RS55415B1 - 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on - Google Patents

7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on

Info

Publication number
RS55415B1
RS55415B1 RS20160960A RSP20160960A RS55415B1 RS 55415 B1 RS55415 B1 RS 55415B1 RS 20160960 A RS20160960 A RS 20160960A RS P20160960 A RSP20160960 A RS P20160960A RS 55415 B1 RS55415 B1 RS 55415B1
Authority
RS
Serbia
Prior art keywords
methyl
diazaspiro
nonan
pyrimidin
trifluoromethyl
Prior art date
Application number
RS20160960A
Other languages
English (en)
Serbian (sr)
Inventor
Gerard M P Giblin
David T Macpherson
David R Witty
Steven J Stanway
Original Assignee
Convergence Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals filed Critical Convergence Pharmaceuticals
Publication of RS55415B1 publication Critical patent/RS55415B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RS20160960A 2012-05-22 2013-05-22 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on RS55415B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261650325P 2012-05-22 2012-05-22
GB201209015A GB201209015D0 (en) 2012-05-22 2012-05-22 Novel compounds
US201361773710P 2013-03-06 2013-03-06
PCT/GB2013/051335 WO2013175205A1 (en) 2012-05-22 2013-05-22 Novel Compounds
EP13725438.9A EP2861602B1 (en) 2012-05-22 2013-05-22 7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one

Publications (1)

Publication Number Publication Date
RS55415B1 true RS55415B1 (sr) 2017-04-28

Family

ID=46546493

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20160960A RS55415B1 (sr) 2012-05-22 2013-05-22 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-on
RS20200393A RS60368B1 (sr) 2012-05-22 2013-05-22 Nova jedinjenja

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20200393A RS60368B1 (sr) 2012-05-22 2013-05-22 Nova jedinjenja

Country Status (27)

Country Link
US (7) US9309254B2 (enEXAMPLES)
EP (3) EP3106464B1 (enEXAMPLES)
JP (3) JP6169687B2 (enEXAMPLES)
KR (2) KR102161101B1 (enEXAMPLES)
CN (2) CN107344942B (enEXAMPLES)
AU (3) AU2013265001B2 (enEXAMPLES)
BR (1) BR112014029280B1 (enEXAMPLES)
CA (1) CA2873956C (enEXAMPLES)
CY (2) CY1118274T1 (enEXAMPLES)
DK (2) DK3106464T3 (enEXAMPLES)
EA (1) EA025579B1 (enEXAMPLES)
ES (3) ES2782088T3 (enEXAMPLES)
GB (1) GB201209015D0 (enEXAMPLES)
HR (2) HRP20161349T1 (enEXAMPLES)
HU (2) HUE049445T2 (enEXAMPLES)
IL (4) IL235805A (enEXAMPLES)
IN (1) IN2014MN02393A (enEXAMPLES)
LT (2) LT3106464T (enEXAMPLES)
MX (1) MX355303B (enEXAMPLES)
PL (2) PL3106464T3 (enEXAMPLES)
PT (2) PT3106464T (enEXAMPLES)
RS (2) RS55415B1 (enEXAMPLES)
SG (2) SG11201407755UA (enEXAMPLES)
SI (2) SI2861602T1 (enEXAMPLES)
SM (2) SMT202000210T1 (enEXAMPLES)
WO (2) WO2013175206A1 (enEXAMPLES)
ZA (1) ZA201408253B (enEXAMPLES)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
US20200255438A1 (en) * 2017-09-28 2020-08-13 Biogen Inc. Novel salts
EP3694510A4 (en) 2017-10-10 2021-06-30 Biogen Inc. SPIRO DERIVATIVE PREPARATION PROCESS
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100564381C (zh) * 2002-07-05 2009-12-02 塔加西普特公司 N-芳基二氮杂螺环化合物及其制备方法和制备药物的用途
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
US7855218B2 (en) 2005-10-10 2010-12-21 Convergence Pharmaceuticals Limited Compounds
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
KR20080059292A (ko) * 2005-10-12 2008-06-26 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 이온 채널 조절인자로서의 바이페닐 유도체
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20110294842A9 (en) 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8759542B2 (en) 2009-09-14 2014-06-24 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide derivatives
GB201122113D0 (en) * 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
WO2013142331A1 (en) * 2012-03-21 2013-09-26 Interdigital Patent Holdings, Inc. Sponsoring of a mobile station session by another mobile station in a wireless network
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
GB201209670D0 (en) 2012-05-31 2012-07-18 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
US9737536B2 (en) 2017-08-22
EP3106464A1 (en) 2016-12-21
PT2861602T (pt) 2016-11-14
JP2015517561A (ja) 2015-06-22
US10010551B2 (en) 2018-07-03
JP6378404B2 (ja) 2018-08-22
SI2861602T1 (sl) 2017-03-31
CN107344942B (zh) 2020-09-25
EP2861594B1 (en) 2016-08-24
GB201209015D0 (en) 2012-07-04
IN2014MN02393A (enEXAMPLES) 2015-08-21
WO2013175205A1 (en) 2013-11-28
AU2013265001A1 (en) 2014-12-18
PL2861602T3 (pl) 2017-05-31
US20160263115A1 (en) 2016-09-15
IL235805A0 (en) 2015-02-01
AU2017201421B2 (en) 2017-12-07
SMT202000210T1 (it) 2020-05-08
MX2014014274A (es) 2015-06-17
EA201492169A1 (ru) 2015-04-30
SMT201600421B (it) 2017-01-10
ES2782088T3 (es) 2020-09-10
WO2013175206A1 (en) 2013-11-28
KR20150023401A (ko) 2015-03-05
CY1123044T1 (el) 2021-10-29
EP2861594A1 (en) 2015-04-22
LT3106464T (lt) 2020-04-10
US20180360833A1 (en) 2018-12-20
PT3106464T (pt) 2020-04-03
EA025579B1 (ru) 2017-01-30
AU2013265001B2 (en) 2016-12-01
ES2602193T3 (es) 2017-02-20
CA2873956A1 (en) 2013-11-28
MX355303B (es) 2018-04-12
SG10201703527WA (en) 2017-06-29
HRP20200580T1 (hr) 2020-10-02
ZA201408253B (en) 2015-12-23
CN104640867A (zh) 2015-05-20
HUE049445T2 (hu) 2020-09-28
HK1209423A1 (en) 2016-04-01
AU2018201653A1 (en) 2018-03-29
HRP20161349T1 (hr) 2017-01-27
JP6169687B2 (ja) 2017-07-26
CA2873956C (en) 2021-03-23
US20200289508A1 (en) 2020-09-17
AU2017201421A1 (en) 2017-03-23
BR112014029280A2 (pt) 2017-06-27
KR102161101B1 (ko) 2020-10-20
LT2861602T (lt) 2016-11-10
US20160184306A1 (en) 2016-06-30
US9376445B2 (en) 2016-06-28
US10485801B2 (en) 2019-11-26
CY1118274T1 (el) 2017-06-28
US20150119404A1 (en) 2015-04-30
IL271330A (en) 2020-01-30
KR20200113027A (ko) 2020-10-05
JP2015517562A (ja) 2015-06-22
DK2861602T3 (en) 2016-11-28
ES2602308T3 (es) 2017-02-20
SI3106464T1 (sl) 2020-12-31
US20150166551A1 (en) 2015-06-18
AU2018201653B2 (en) 2019-05-02
DK3106464T3 (da) 2020-03-23
IL252033B (en) 2019-12-31
EP2861602A1 (en) 2015-04-22
RS60368B1 (sr) 2020-07-31
EP2861602B1 (en) 2016-08-10
IL271330B (en) 2021-02-28
BR112014029280B1 (pt) 2022-10-04
HUE031664T2 (en) 2017-07-28
US9309254B2 (en) 2016-04-12
CN104640867B (zh) 2017-07-21
PL3106464T3 (pl) 2020-11-16
EP3106464B1 (en) 2020-01-08
IL252033A0 (en) 2017-06-29
US20170304303A1 (en) 2017-10-26
IL280595A (en) 2021-03-25
IL235805A (en) 2017-05-29
SG11201407755UA (en) 2014-12-30
JP2017206534A (ja) 2017-11-24
CN107344942A (zh) 2017-11-14

Similar Documents

Publication Publication Date Title
AP2012006192A0 (en) PyrroloÄ2,3-DÜ pyrimidine compounds.
DK2364624T3 (da) Kaffedriksystem, kaffebrygningsapparat
AP2012006242A0 (en) Anticoagulant antidotes.
SMT201600421B (it) 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-one
EP2573067A4 (en) AROMATIC BUTANE-2-OL COMPOUNDS AND MANUFACTURING METHOD AND USES THEREOF
Raloff Plastics ingredient raises concern
GEAR Product Sheet
郑振云 et al. 激电测量法在青海南戈滩矿区中的找矿应用效果
Grewal When Nice Guys Finish First
YODER DATABYTES
Rodriguez Your eyes, your self
Crenson Stories worth losing sleep over
王彦玮 et al. 山东望儿山金矿地表沉陷数值模拟研究
赵景博 et al. 多井提升平行作业在井巷工程施工中的应用
Bower Wandering mind is unhappy mind
Agerstam The Courtyard
Saey Friendly bacteria may initiate MS
Bargiel Intermezzo für Orchester, op. 46. Partitur.
Marco Aguilar Six Houses, Paired 2-2
Cowen Billions, billions and more billions
朱松亚 Photo
王贵春 et al. 中蒙边境成矿带金矿床类型及找矿方向
李涛 et al. 赤峰柴胡栏子金矿区矿体成矿规律及其找矿应用
Schumann Symphonie Nr. 1, B dur, op. 38. Partitur.
Beethoven Symphonie Nr. 4, B dur, Op. 60. Partitur.